Molecular characterization of AML with RUNX1-RUNX1T1 at diagnosis and relapse reveals net loss of co-mutations

AML with RUNX1-RUNX1T1 fusion is a WHO entity with a favorable outcome following intensive chemotherapy. The absence of RUNX1-RUNX1T1 transcripts in remission defines complete molecular response and correlates with a superior survival. However, a significant proportion of patients still relapses and...

Descripción completa

Detalles Bibliográficos
Autores principales: Höllein, Alexander, Nadarajah, Niroshan, Meggendorfer, Manja, Jeromin, Sabine, Kern, Wolfgang, Haferlach, Claudia, Haferlach, Torsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745937/
https://www.ncbi.nlm.nih.gov/pubmed/31723813
http://dx.doi.org/10.1097/HS9.0000000000000178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745937/
https://www.ncbi.nlm.nih.gov/pubmed/31723813
http://dx.doi.org/10.1097/HS9.0000000000000178

Ejemplares similares